
“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”
This study is comparing olaparib on its own and in combination with AZD6738 for triple negative breast cancer that has spread.
To take part in the study, the team want to know if your cancer has changes () in the
of the HRR (Human Recombination Repair) proteins. For this test, they use a piece of tissue that was taken when you were first diagnosed with breast cancer. Or a piece of tissue that was collected later from a part of the body to which the cancer had spread.
This study was also looking at AZD1775 in combination with olaparib. But this combination is no longer been used.
You have treatment in cycles.
Olaparib only
Every 4 weeks is a cycle of treatment. Olaparib tablets are taken twice a day every day.
You can take them with food (a light meal) or without food. You have to take them 12 hours apart.
AZD6738 and olaparib
Every 4 weeks is a cycle of treatment.
AZD6738 are tablets you take once a day.
You take them for the 1st week (7 days) of each 4 week cycle. You must not eat or drink anything, apart from water, for at least 2 hours before taking the tablets and for at least an hour after.
You also take olaparib tablets twice a day every day.
AZD1775 and olaparib
The panel monitoring the safety of people in the study recommended to stop using AZD1775. This was due to the side effects. So people are no longer being put into this group.
Everyone in this group could continue having orlaparib only.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Andrew Tutt
AstraZeneca
PAREXEL
Freephone 0808 800 4040
“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”